Cardiorenal syndrome: New developments in the understanding and pharmacologic management

Clinical Journal of the American Society of Nephrology

Volumn 8, Issue 10, 2013, Pages 1808-1815

  House, Andrew A ^a  

^a WESTERN UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOBUTAMINE; ENALAPRIL; EPLERENONE; FUROSEMIDE; GLYCERYL TRINITRATE; LEVOSIMENDAN; NESIRITIDE; NITROPRUSSIDE SODIUM; PHOSPHODIESTERASE INHIBITOR; PLACEBO; SERELAXIN; SPIRONOLACTONE; VALSARTAN;

ARTICLE; CARDIOGENIC SHOCK; CARDIORENAL SYNDROME; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG DOSE COMPARISON; ELECTROLYTE DISTURBANCE; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART MUSCLE INJURY; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOTENSION; KIDNEY FUNCTION; KIDNEY PERFUSION; MORTALITY; PATHOPHYSIOLOGY; POST HOC ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; ULTRAFILTRATION;

CARDIO-RENAL SYNDROME; GLOMERULAR FILTRATION RATE; HUMANS;

EID: 84885230136     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.02920313     Document Type: Article

References (43)

1. House AA, Anand I, Bellomo R, Cruz D, Bobek I, Anker SD, Aspromonte N, Bagshaw S, Berl T, Daliento L, Davenport A, Haapio M, Hillege H, McCullough P, Katz N, Maisel A, Mankad S, Zanco P, Mebazaa A, Palazzuoli A, Ronco F, Shaw A, Sheinfeld G, Soni S, Vescovo G, Zamperetti N, Ponikowski P, Ronco C; Acute Dialysis Quality Initiative Consensus Group: Definition and classification of Cardio-Renal Syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 25: 1416-1420, 2010
2. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW; American College of Cardiology Foundation; American Heart Association: 2009 Focused update incorporated into the ACC/ AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 53: e1-e90, 2009
3. Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K; ESC Committee for Practice Guidelines (CPG): ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 10: 933-989, 2008
4. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A; Acute Kidney Injury Network: Acute Kidney Injury Network: Report of an initiative to improve outcomes in acute kidney injury. Crit Care 11: R31, 2007
5. Damman K, Navis G, Voors AA, Asselbergs FW, Smilde TD, Cleland JG, van Veldhuisen DJ, Hillege HL: Worsening renal function and prognosis in heart failure: Systematic review and meta-analysis. J Card Fail 13: 599-608, 2007
6. Sweitzer NK, Lopatin M, Yancy CW, Mills RM, Stevenson LW: Comparison of clinical features and outcomes of patients hospitalized with heart failure and normal ejection fraction (. or 555%) versus those with mildly reduced (40% to 55%) and moderately to severely reduced (,40%) fractions. Am J Cardiol 101: 1151-1156, 2008
7. Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL: Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 9: 872-878, 2007
8. Mullens W, Abrahams Z, Skouri HN, Francis GS, Taylor DO, Starling RC, Paganini E, Tang WH: Elevated intra-abdominal pressure in acute decompensated heart failure: A potential contributor to worsening renal function? J Am Coll Cardiol 51: 300-306, 2008
9. Dupont M, Mullens W, Finucan M, Taylor DO, Starling RC, Tang WH: Determinants of dynamic changes in serum creatinine in acute decompensated heart failure: The importance of blood pressure reduction during treatment. Eur J Heart Fail 15: 433-440, 2013
10. House AA, Haapio M, Lassus J, Bellomo R, Ronco C: Therapeutic strategies for heart failure in cardiorenal syndromes. Am J Kidney Dis 56: 759-773, 2010
11. Kleinfelder H: Experimental studies and clinical trials of a new diuretic. Dtsch Med Wochenschr 88: 1695-1702, 1963
12. Marenzi G, Lauri G, Grazi M, Assanelli E, Campodonico J, Agostoni P: Circulatory response to fluid overload removal by extracorporeal ultrafiltration in refractory congestive heart failure. J Am Coll Cardiol 38: 963-968, 2001
13. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP: Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 122: 265-272, 2010
14. Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, LeWinter MM, Deswal A, Rouleau JL, Ofili EO, Anstrom KJ, Hernandez AF, McNulty SE, Velazquez EJ, Kfoury AG, Chen HH, Givertz MM, Semigran MJ, Bart BA, Mascette AM, Braunwald E, O'Connor CM; NHLBI Heart Failure Clinical Research Network: Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 364: 797-805, 2011
15. Bart BA, Goldsmith SR, Lee KL, Givertz MM, O'Connor CM, Bull DA, Redfield MM, Deswal A, Rouleau JL, LeWinter MM, Ofili EO, Stevenson LW, Semigran MJ, Felker GM, Chen HH, Hernandez AF, Anstrom KJ, McNulty SE, Velazquez EJ, Ibarra JC, Mascette AM, Braunwald E; Heart Failure Clinical Research Network: Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 367: 2296-2304, 2012
16. Margulies KB, Burnett JC Jr: Atrial natriuretic factor modulates whole kidney tubuloglomerular feedback. Am J Physiol 259: R97-R101, 1990
17. Neuhofer W, Pittrow D: Role of endothelin and endothelin receptor antagonists in renal disease. Eur J Clin Invest 36[Suppl 3]: 78-88, 2006
18. Vallon V, Miracle C, Thomson S: Adenosine and kidney function: Potential implications in patients with heart failure. Eur J Heart Fail 10: 176-187, 2008
19. Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ: The endothelin system as a therapeutic target in cardiovascular disease: Great expectations or bleak house? Br J Pharmacol 153: 1105-1119, 2008
20. Coletta AP, Cleland JG: Clinical trials update: highlights of the scientific sessions of the XXIII Congress of the European Society of Cardiology-WARIS II, ESCAMI, PAFAC, RITZ-1 and TIME. Eur J Heart Fail 3: 747-750, 2001
21. McMurray JJ, Teerlink JR, Cotter G, Bourge RC, Cleland JG, Jondeau G, Krum H, Metra M, O'Connor CM, Parker JD, TorreAmione G, van Veldhuisen DJ, Lewsey J, Frey A, Rainisio M, Kobrin I; VERITAS Investigators: Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials. JAMA 298: 2009-2019, 2007
22. Voors AA, Dittrich HC, Massie BM, DeLucca P, Mansoor GA, Metra M, Cotter G, Weatherley BD, Ponikowski P, Teerlink JR, Cleland JG, O'Connor CM, Givertz MM: Effects of the adenosine A1 receptor antagonist rolofylline on renal function in patients with acute heart failure and renal dysfunction: results from PROTECT (Placebo-Controlled Randomized Study of the Selective Adenosine A1 Receptor Antagonist Rolofylline for Patients Hospitalized with Acute Decompensated Heart Failure and Volume Overload to Assess Treatment Effect on Congestion and Renal Function). J Am Coll Cardiol 57: 1899-1907, 2011
23. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 297: 1332-1343, 2007
24. O'Connor CM, Starling RC, Hernandez AF, Armstrong PW, Dickstein K, Hasselblad V, Heizer GM, Komajda M, Massie BM, McMurray JJ, Nieminen MS, Reist CJ, Rouleau JL, Swedberg K, Adams KF Jr, Anker SD, Atar D, Battler A, Botero R, Bohidar NR, Butler J, Clausell N, Corbalán R, Costanzo MR, Dahlstrom U, Deckelbaum LI, Diaz R, Dunlap ME, Ezekowitz JA, Feldman D, Felker GM, Fonarow GC, Gennevois D, Gottlieb SS, Hill JA, Hollander JE, Howlett JG, Hudson MP, Kociol RD, Krum H, Laucevicius A, Levy WC, Méndez GF, Metra M, Mittal S, Oh BH, Pereira NL, Ponikowski P, Tang WH, Tanomsup S, Teerlink JR, Triposkiadis F, Troughton RW, Voors AA, Whellan DJ, Zannad F, Califf RM: Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 365: 32-43, 2011
25. Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M; Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIMECHF) Investigators: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: A randomized controlled trial. JAMA 287: 1541-1547, 2002
26. Landoni G, Biondi-Zoccai G, Greco M, Greco T, Bignami E, Morelli A, Guarracino F, Zangrillo A: Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 40: 634-646, 2012
27. Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M; SURVIVE Investigators: Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial. JAMA 297: 1883-1891, 2007
28. Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I: Levosimendan improves renal function in patients with acute decompensated heart failure: Comparison with dobutamine. Cardiovasc Drugs Ther 21: 431-435, 2007
29. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): A randomised, placebo-controlled trial. Lancet 381: 29-39, 2013
30. Metra M, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld L, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Prescott MF, Edwards C, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin T, Teerlink JR; RELAX-AHF Investigators: Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes. J Am Coll Cardiol 61: 196-206, 2013
31. Fonarow GC: Comparative effectiveness of diuretic regimens. N Engl J Med 364: 877-878, 2011
32. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nabi AH, Suzuki F, Nagai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A: Renal sympathetic denervation suppresses de novo podocyte injury and albuminuria in rats with aortic regurgitation. Circulation 125: 1402-1413, 2012
33. Haapio M, House AA, de Cal M, Cruz DN, Lentini P, Giavarina D, Fortunato A, Menghetti L, Salgarello M, Lupi A, Soffiati G, Fontanelli A, Zanco P, Ronco C: Heart-kidney biomarkers in patients undergoing cardiac stress testing. Int J Nephrol 2011: 425923, 2011
34. Tanaka M, Yoshida H, Furuhashi M, Togashi N, Koyama M, Yamamoto S, Yamashita T, Okazaki Y, Ishimura S, Ota H, Hasegawa T, Miura T: Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in the tubulointerstitium. Intern Med 50: 2877-2887, 2011
35. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435, 1987
36. Ljungman S, Kjekshus J, Swedberg K: Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS] Trial). Am J Cardiol 70: 479-487, 1992
37. The SOLVD Investigators: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors. N Engl J Med 327: 685-691, 1992
38. Knight EL, Glynn RJ, McIntyre KM, Mogun H, Avorn J: Predictors of decreased renal function in patients with heart failure during angiotensin-converting enzyme inhibitor therapy: Results from the studies of left ventricular dysfunction (SOLVD). Am Heart J 138: 849-855, 1999
39. Khan NA, Ma I, Thompson CR, Humphries K, Salem DN, Sarnak MJ, Levin A: Kidney function and mortality among patients with left ventricular systolic dysfunction. J Am Soc Nephrol 17: 244-253, 2006
40. Hillege HL, van Gilst WH, van Veldhuisen DJ, Navis G, Grobbee DE, de Graeff PA, de Zeeuw D; CATS Randomized Trial: Accelerated decline and prognostic impact of renal function after myocardial infarction and the benefits of ACE inhibition: The CATS randomized trial. Eur Heart J 24: 412-420, 2003
41. Rossignol P, Cleland JG, Bhandari S, Tala S, Gustafsson F, Fay R, Lamiral Z, Dobre D, Pitt B, Zannad F: Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: Insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125: 271-279, 2012
42. Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ; Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators: The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 380: 1387-1395, 2012
43. Pitt B, Filippatos G, Gheorghiade M, Kober L, Krum H, Ponikowski P, Nowack C, Kolkhof P, Kim SY, Zannad F: Rationale and design of ARTS: A randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease. Eur J Heart Fail 14: 668-675, 2012